On March 1, 2021 Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, reported that Dan Menichella, President and Chief Executive Officer of Kaleido will present a corporate overview and host 1×1 meetings with investors during Chardan’s 3rd Annual Microbiome Medicines Summit (Press release, Kaleido Biosciences, MAR 1, 2021, View Source [SID1234575862]). The presentation will take place virtually on Monday, March 8th at 9:30am-9:55am EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation can be accessed on the Investors & Media section of Kaleido’s website at View Source An archived replay will be available for 90 days following the event.